marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-04-2024
Precision BioSciences Balance Sheet 2011-2024 | DTIL
Annual Balance Sheet Precision BioSciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-108 M | -166 M | -139 M | -79.3 M | -181 M | -103 M | -62.8 M | - | - | - | - | - | - |
Long Term Debt |
7.72 M | 22.2 M | 2.48 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.13 M | 1.68 M | 1.82 M | 1.93 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 62.9 M | 70 M | 84.6 M | 89.8 M | - | - | - | - | - | - |
Total Current Liabilities |
50 M | 59.7 M | 36 M | 42.8 M | 26.9 M | - | - | - | - | - | - | - | - |
Total Liabilities |
141 M | 178 M | 120 M | 106 M | 96.9 M | 98.6 M | 99.1 M | - | - | - | - | - | - |
Deferred Revenue |
12 M | 46.2 M | 21.2 M | 30.2 M | 16.5 M | 8.44 M | 5.82 M | - | - | - | - | - | - |
Retained Earnings |
-490 M | -428 M | -317 M | -286 M | -177 M | -85.2 M | -39.1 M | - | - | - | - | - | - |
Total Assets |
160 M | 238 M | 211 M | 150 M | 235 M | 139 M | 72.7 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
117 M | 190 M | 144 M | 89.8 M | 181 M | 103 M | - | - | - | - | - | - | - |
Book Value |
18.9 M | 60.4 M | 91.2 M | 44.4 M | 138 M | 40 M | -26.4 M | - | - | - | - | - | - |
Total Shareholders Equity |
18.9 M | 60.4 M | 91.2 M | 44.4 M | 138 M | 40 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Precision BioSciences
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
6.75 M | 7.09 M | 7.41 M | 7.72 M | - | 3.17 M | 22.3 M | 22.2 M | 22.2 M | 22.1 M | 2.48 M | 2.48 M | 6.97 M | 7.52 M | 8.06 M | 8.59 M | 8.59 M | 8.59 M | 8.59 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
88.4 M | 91.1 M | 148 M | 141 M | 135 M | 148 M | 164 M | 178 M | 187 M | 194 M | 112 M | 120 M | 126 M | 130 M | 203 M | 106 M | 106 M | 106 M | 106 M | 96.9 M | 96.9 M | 96.9 M | 96.9 M | 98.6 M | 98.6 M | 98.6 M | 98.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
175 K | 526 K | 2.41 M | 12 M | 17.4 M | 23.8 M | 38.3 M | 46.2 M | 48.4 M | 41.5 M | 19.7 M | 21.2 M | 22 M | 22.2 M | 53.1 M | 30.2 M | 30.2 M | 30.2 M | 30.2 M | 16.5 M | 10.8 M | 16.5 M | 16.5 M | 8.44 M | 8.44 M | 8.44 M | 8.44 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-465 M | -448 M | -481 M | -490 M | -473 M | -465 M | -453 M | -428 M | -400 M | -376 M | -345 M | -317 M | -294 M | -283 M | -305 M | -286 M | -286 M | -286 M | -286 M | -177 M | -177 M | -177 M | -177 M | -85.2 M | -85.2 M | -85.2 M | -85.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
153 M | 166 M | 185 M | 160 M | 164 M | 182 M | 205 M | 238 M | 272 M | 297 M | 181 M | 211 M | 227 M | 230 M | 262 M | 150 M | 150 M | 150 M | 150 M | 235 M | 235 M | 235 M | 235 M | 139 M | 139 M | 139 M | 139 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
98.8 M | 124 M | 138 M | 117 M | 122 M | 138 M | 158 M | 190 M | 212 M | 184 M | 116 M | 144 M | 160 M | 174 M | 193 M | 89.8 M | 89.8 M | 89.8 M | 89.8 M | 181 M | 181 M | 181 M | 181 M | 103 M | 103 M | 103 M | 103 M | 62.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
64.9 M | 74.7 M | 37.2 M | 18.9 M | 29.1 M | 34 M | 40.2 M | 60.4 M | 84.4 M | 103 M | 69.7 M | 91.2 M | 101 M | 101 M | 58.8 M | 44.4 M | 44.4 M | 44.4 M | 44.4 M | 138 M | 138 M | 138 M | 138 M | 40 M | 40 M | 40 M | 40 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
64.9 M | 74.7 M | 37.2 M | 18.9 M | 29.1 M | 34 M | 40.2 M | 60.4 M | 84.4 M | 103 M | 69.7 M | 91.2 M | 101 M | 101 M | 58.8 M | 44.4 M | 44.4 M | 44.4 M | 44.4 M | 138 M | 138 M | 138 M | 138 M | 40 M | 40 M | 40 M | 40 M | -26.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency